Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 102

Results For "approval"

2612 News Found

LANXESS marks 40 yrs of animal disease defense 'Virkon S'
News | March 20, 2026

LANXESS marks 40 yrs of animal disease defense 'Virkon S'

A disinfectant credited with helping contain some of the world’s most dangerous livestock diseases is marking a major milestone


Strides acquires generic brands from Sandoz to boost Africa business
News | March 19, 2026

Strides acquires generic brands from Sandoz to boost Africa business

The initial consideration for the transaction is US$ 12 million


Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
News | March 18, 2026

Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis

ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025


Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients
Drug Approval | March 18, 2026

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options


EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers
News | March 17, 2026

EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers

AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible


QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system
News | March 16, 2026

QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system

The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise


GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
News | March 16, 2026

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk


First patient dosed in trial of novel drug targeting limb-threatening artery disease
News | March 16, 2026

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts


China’s NMPA approves Zydus-licensed anaemia drug Desidustat
News | March 15, 2026

China’s NMPA approves Zydus-licensed anaemia drug Desidustat

Desidustat tablets are a novel oral HIF-PHI approved for treating anaemia in non-dialysis adult CKD patients